Fatty liver disease (MASLD/MASH) trials in India

In India 18 Also abroad 367

18 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

No phaseTaking people
Pathogenesis of Chronic Kidney Disease Associated With Metabolic Dysfunction- Associated Fatty Liver Disease (MAFLD) and Treatment Response of Oral Semaglutide.
Where
New Delhi
Age
18 years and over
People
90
Run by
Institute of Liver and Biliary Sciences, India
See details and how to joinNCT07391267
Phase 3Taking people
A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
Where
Chandigarh, Coimbatore, Dahegaon, Hyderabad, Jaipur, Kolkata, Mumbai, Mysore, Nagpur, New Delhi, Pune, Secunderabad, Surat, Thiruvananthapuram, Vadodara, Varanasi
Age
18 years to 80 years
People
1,650 worldwide
Run by
Akero Therapeutics, Inc
See details and how to joinNCT06215716
Phase 3Taking people
LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
Where
Ahemdabad, Chandigarh, Hyderabad, Afzalgunj, Jaipur, Lucknow, Mohali, Nagpur, New Delhi, Rohtak, Secunderabad, Surat
Age
18 years and over
People
1,800 worldwide
Run by
Boehringer Ingelheim
See details and how to joinNCT06632444 · EU 2024-513739-25-00
Phase 3Taking people
LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
Where
Ahemdabad, Chandigarh, Hyderabad, Afzalgunj, Jaipur, Lucknow, Nagpur, New Delhi, Rohtak, Secunderabad, Surat
Age
18 years and over
People
1,590 worldwide
Run by
Boehringer Ingelheim
See details and how to joinNCT06632457 · EU 2024-513741-36-00
Phase 2Not yet taking people in India
Qurse Revand for MASLD: A Randomized Controlled Safety and Efficacy Trial
Where
Bangalore
Age
20 years to 60 years
People
128
Run by
National Institute of Unani Medicine, Bengaluru
See details and how to joinNCT07902219
Phase 3Taking people
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
Where
Allahābād, Bhubaneswar, Gujrāt, Guwahati, Kolkata, Nagpur, New Delhi, Sūrat, Wardha
Age
18 years to 80 years
People
1,350 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT06318169 · EU 2023-509912-27-00
Phase 3Taking people
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
Where
Gujrāt, Prayagraj, Rajpur Sonarpur, Sūrat, Wardha
Age
18 years to 75 years
People
1,800 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT06419374 · EU 2023-510395-31-00
Phase 3Taking people
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
Where
Chandigarh, Coimbatore, Hyderabad, Jaipur, Kolkata, Ludhiana, Mumbai, Mysore, Nagpur, New Delhi, Pune, Rishikesh, Surat, Thiruvananthapuram, Vadodara, Varanasi
Age
18 years to 80 years
People
2,150 worldwide
Run by
Akero Therapeutics, Inc
See details and how to joinNCT06528314
Phase 3Taking people
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
Where
Ahmedabad, Bhubaneswar, Chandigarh, Ernākulam, Guntur, Hyderabad, Jaipur, Kochi, Kolkata, Lucknow, Ludhiana, Mohali, Mumbai, Mysore, Nagpur, New Delhi, Rishikesh, Surat, Wardha
Age
18 years and over
People
4,500 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07165028 · EU 2025-522674-36-00
Phase 4Taking people
Fibrosis Lessens After Metabolic Surgery
Where
Indore, Mumbai
Age
18 years to 75 years
People
120 worldwide
Run by
The Cleveland Clinic
See details and how to joinNCT06374875
No phaseTaking people
Influence of Donor and Recipient Genetic Polymorphisms on Graft Steatosis After Liver Transplant
Where
New Delhi
Age
18 years and over
People
50
Run by
Institute of Liver and Biliary Sciences, India
See details and how to joinNCT07685353
No phaseNot yet taking people in India
Safety and Efficacy of Finerenone in Metabolic Dysfunction Associated Steatotic Liver Disease(MASLD/NAFLD) Related Cirrhosis Patients With Ascites in Prevention of Chronic Kidney Disease.
Where
New Delhi
Age
18 years to 80 years
People
160
Run by
Institute of Liver and Biliary Sciences, India
See details and how to joinNCT07585526
No phaseEnrolling by invitation
Efficacy and Safety of Picroliv in Patients With Non-Alcoholic Fatty Liver Disease
Where
Chandigarh, Chowk, Delhi, Mumbai, Panjagutta, Vasant Kunj
Age
18 years to 60 years
People
170
Run by
Bioagile Therapeutics Pvt. Ltd.
See details and how to joinNCT07452744
No phaseTaking people
Comorbidities Resolution After MGB Surgery and Change in Body Composition
Where
Bhubaneswar
Age
18 years to 65 years
People
35
Run by
All India Institute of Medical Sciences, Bhubaneswar
See details and how to joinNCT06015620
No phaseTaking people
Effect of Indianized Version of Mediterranean Diet vs. Low Fat Diet on Hepatic Steatosis in Overweight Children and Adolescent With MASLD
Where
New Delhi
Age
8 years to 18 years
People
134
Run by
Institute of Liver and Biliary Sciences, India
See details and how to joinNCT06768216
No phaseTaking people
Effect of Bempedoic Acid on Liver Fat in Individuals With Nonalcoholic Fatty Liver Disease and Type 2 Diabetes
Where
Gurgaon
Age
20 years and over
People
100
Run by
Medanta, The Medicity, India
See details and how to joinNCT06035874
No phaseTaking people
Cardiac Dysfunction in Patients with Fatty Liver Disease
Where
Chandigarh
Age
18 years to 65 years
People
150
Run by
Post Graduate Institute of Medical Education and Research, Chandigarh
See details and how to joinNCT06386094
No phaseNot yet taking people in India
Effect of High Protein Diet on Hepatic Steatosis in Patients With MAFLD
Where
Delhi
Age
18 years to 60 years
People
140
Run by
Institute of Liver and Biliary Sciences, India
See details and how to joinNCT06749704